Animesh Pardanani on Muck Rack

Animesh Pardanani

As seen in: Blood Cancer Journal, Nature, Wiley Online Library, JAMA (The Journal of the American Medical Association), JAMA Oncology, The New England Journal of Medicine, Blood
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Animesh

Contact Animesh, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

American Journal of Hematology

|
By Animesh Pardanani
| Wiley Online Library Verified
Open in Who Shared Issue with article?

CMML2AML: machine-learning discovery of co-mutations and specific single mutations predictive of blast transformation in chronic myelomonocytic leukemia

|
By Saubia Fathima, Lior Rokach, Muhammad Yousuf, Priyansh Faldu, Ali Alsugair, Clifford M. Csizmar, Merry Nakhleh, Abhishek A. Mangaonkar, Animesh Pardanani, Luca Lanino, Alessia Campagna, Giulia Maggioni, Noushin Farnoud, Raajit Rampal, Kaaren K. Reichard, Rong Lucy He, Naseema Gangat Verified, Mrinal Patnaik, Matteo Della Porta, Ayalew Tefferi
| Nature Verified
Abstract Contemporary risk models in chronic myelomonocytic leukemia (CMML) focus on the prognostic relevance of individual rather than concurrent mutations. In the current study of 605 Mayo Clinic patients with CMML, we applied machine-learning algorithms in order to examine the influence of cooperative mutational interactions on blast transformation (BT).
Open in Who Shared Issue with article?

CPX-351 (Liposomal Cytarabine and Daunorubicin) versus venetoclax plus hypomethylating agent therapy in newly diagnosed acute myeloid leukemia: a retrospective comparison involving 600 Mayo Clinic patients

|
By Saubia Fathima, Lior Rokach, Nour Ghosoun, Mahsa RezaSoltani, Rimal Ilyas, Ali Alsugair, Kristen B. McCullough, Maymona G. Abdelmagid, Aref Al-Kali, Hassan B. Alkhateeb, Kebede H. Begna, Abhishek A. Mangaonkar, Aasiya Matin, Antoine Saliba, Mehrdad Hefazi Torghabeh, Mark Litzow, William Hogan, Mithun V. Shah, Mrinal Patnaik, Animesh Pardanani, Talha Badar, Hemant S. Murthy, James M. Foran, Jeanne Palmer, Nathan Punwani, Lisa Sproat, Nandita Khera, Ayalew Tefferi, Naseema Gangat Verified, Cecilia Arana Yi
| Nature Verified
Abstract The comparative value of liposomal cytarabine/daunorubicin (CPX-351) versus venetoclax plus a hypomethylating agent (Ven-HMA) in the frontline treatment of older adults with primary (de novo) or secondary acute myeloid leukemia (AML) remains uncertain. In the current study, we retrospectively examined outcomes of 600 patients with newly diagnosed AML treated with CPX-351 (N = 112) or Ven-HMA (N = 488).
Open in Who Shared Issue with article?
See all 23 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified